Ontology highlight
ABSTRACT:
SUBMITTER: Lassen U
PROVIDER: S-EPMC3322959 | biostudies-literature | 2012 Feb
REPOSITORIES: biostudies-literature
Lassen U U Nielsen D L DL Sørensen M M Winstedt L L Niskanen T T Stenberg Y Y Pakola S S Stassen J-M JM Glazer S S
British journal of cancer 20120124 4
<h4>Background</h4>TB-403 (RO 5323441), a humanised monoclonal antibody, is a novel antiangiogenesis agent directed against placental growth factor. The safety, pharmacokinetics (PK), and antitumour activity of TB-403 were assessed in a phase I, dose-escalation study in patients with advanced solid tumours.<h4>Methods</h4>Patients in sequential dose groups received either weekly doses of 1.25, 5.0, or 10 mg kg(-1) or doses of 20 or 30 mg kg(-1) every third week.<h4>Results</h4>Twenty-three patie ...[more]